Search Results

Algernon Announces Enrollment of First Patient in 2b/3 Human Study of Ifenprodil for Treatment of COVID-19 NCOUVER, British Columbia, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it has enrolled its first patient in its multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19. The countries participating in the study include the U.S., Australia, Romania and the Philippines. “On March 6th, 2020 the company announced it had decided to explore Ifenprodil as a possible treatment for COVID-19 and 5 months later we have now begun a Phase 2b/3 human trial,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals. “We look forward to a speedy enrollment of the balance of the patients and we remain hopeful in Ifenprodil’s potential as a therapeutic that will reduce both the severity and duration of a COVID-19 infection.” Background The Company announced on March 06, 2020 that it was going to explore Ifenprodil as a possible treatment for COVID-19 when it discovered an independent research study that showed the drug was active in an animal model for H5N1, the world’s most lethal avian flu, with an approximately 60% mortality rate in humans. In the study, Ifenprodil reduced mortality by 40% and reduced acute lung injury and inflammation in the lung tissue. On July 21, 2020 the Company highlighted a study undertaken by UT Dallas that identified a dramatic upregulation of NMDA receptors in immune cells in the lungs of COVID-19 patients. The study went on to identify possible drug candidates, including Ifenprodil, that could interfere with the receptor’s glutamate signalling pathway and as a result possibly reduce the severity and duration of a COVID infection. Ifenprodil is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (Glu2NB) preventing glutamate signalling. Coupled with the Company’s own animal data showing Ifenprodil’s reduction of lung fibrosis in two separate studies, and its efficacy in an animal model for acute cough, the Company is investigating Ifenprodil to determine if it can reduce the severity and duration of a COVID infection. Phase 2b/3 Study Protocol Summary The Company’s multinational Phase 2b/3 human trial for COVID-19 is entitled, "A Randomized Open Label Phase 2b/3 Study of the Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patients with Confirmed COVID-19 Disease." The trial will begin as a Phase 2b study of an aggregate of 150 patients. With positive preliminary data, the clinical trial will move directly into a Phase 3 trial. The data will determine the number of expected patients needed to reach statistical significance in the Phase 3 trial. Patients will be randomized in a one-to-one manner and will either be treated using an existing standard of care, or standard of care plus Ifenprodil 60 mg (taken as one 20 mg tablet three-times daily) for one arm or standard of care plus Ifenprodil 120 mg (taken as two 20 mg tablets three-times daily) for two weeks. Over the testing period, doctors will observe whether there is an improvement in a number of secondary endpoints, including mortality, blood oxygen levels, time spent in intensive care and time to mechanical ventilation. Phase 2b Study Completion and Data Readout Now that the study has begun, the Company will make an assessment of the enrollment rate and will provide an update to the market in due course on a projected completion date as well as when the read out of the data can be expected. About NP-120 (Ifenprodil) NP-120 (Ifenprodil) is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (Glu2NB). Ifenprodil prevents glutamate signalling. The NMDA receptor is found on many tissues including lung cells, T-cells, and neutrophils. The Company believes NP-120 can reduce the infiltration of neutrophils and T-cells into the lungs where they can release glutamate and cytokines respectively. The latter can result in the highly problematic cytokine storm that contributes to the loss of lung function and ultimately death as has been reported in COVID-19 infected patients. About Algernon Pharmaceuticals Inc. Algernon is a drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing. Algernon has filed new intellectual property rights globally for NP-120 (Ifenprodil) for the treatment of respiratory diseases and is working to develop a proprietary injectable and slow release formulation. The Compay is not making any express or implied claims that NP-120 (Ifenprodil) is an effective treatment for COVID-19. CONTACT INFORMATION Christopher J. Moreau CEO Algernon Pharmaceuticals Inc. 604.398.4175 ext 701 info@algernonpharmaceuticals.com investors@algernonpharmaceuticals.com www.algernonpharmaceuticals.com The CSE does not accept responsibility for the adequacy or accuracy of this release. Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law. SOURCE #Technology #MedicalTechnology #Medtech #DrugDiscovery #MedicalResearch #MedicalDevices #PharmaceuticalDevelopment #BreathAnalysis #FAIMS #DrugRepurosing #RespiratoryMedicine #RespiratoryIllness #ClinicalTrials #HumanTrials #MedicalTechnology #MedicalAdvancements #DrugDevelopment #Research #MedicalBreakthrough #Coronavirus #COVID19 #Biotech #BiotechStocks #InvestinginHealthcare #InvestinginMedicine #SmallCapStocks #FrontierMCG

August 31st, 2020 Erin Ventures Inc. [TSXV: EV] reports that it has filed its compulsory Annual Work Report and License Extension Application for its Piskanja Boron Project, as required by the Serbian Law on Mining and Geological Exploration. In accordance with these regulations, Erin has notified the Mining Ministry of its intention to proceed with the “Certification of Reserves” process, which consists primarily of the submission of a Serbian compliant Mineral Resource Calculation and Technical Economic Assessment. The law affords Erin up to 3 years (from the date of the license extension approval) on this license phase, and requires Erin to complete the necessary studies and gain approval for the “Certification of Reserves” as well as the “Approval of the Exploitation Field”, as the first two (of three) steps in the mine licensing process. Piskanja is Erin’s wholly owned boron deposit with an indicated mineral resource of 7.8 million tonnes (averaging 31.0 per cent B2O3), and an inferred resource of 3.4 million tonnes (averaging 28.6 per cent B2O3), calculated in accordance with the Canadian Institute of Mining Definition Standards on Mineral Resources and Reserves (CIM Standards), as disclosed in Erin’s report titled, “Mineral Resource Estimate Update On The Piskanja Borate Project, Serbia, October 2016 - Amended February 28 2019” - prepared by SRK Consulting (UK) Ltd. The responsible persons for the updated MRE are Dr Mike Armitage (C.Eng. C.Geol.) and Dr Mikhail Tsypukov who are both full time employees of SRK and Qualified Persons in accordance with the CIM Definition Standards on Mineral Resources and Reserves (CIM Standards) and independent of Erin Ventures. On behalf of the Board of Directors, Blake Fallis, General Manager About Erin Ventures Erin Ventures Inc. is an international mineral exploration and development company with boron assets in Serbia. Headquartered in Victoria, B.C., Canada, Erin's shares are traded on the TSX Venture Exchange under the symbol "EV". For detailed information please see Erin's website at www.erinventures.com or the Company's filed documents at www.sedar.com. For further information, please contact: Erin Ventures Inc. Blake Fallis, General Manager Phone: 1-250- 384-1999 or 1-888-289-3746 info@erinventures.com www.erinventures.com Erin’s Public Quotations Canada TSX Venture: EV USA SEC12G3-2(B)#82-4432 Europe Berlin: EKV The technical information in this release was prepared and approved by James E Wallis, M.Sc. (Eng), P. Eng., a director of the company, who is a Qualified Person under National Instrument 43-101. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward Looking Statements: Certain statements in this news release may constitute forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include, but are not limited to, statements concerning  anticipated approvals; and results of the completion of the transactions contemplated in this news release. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "outlook", "objective", "may", "will", "expect", "intend", "estimate", "anticipate", "believe", "should", "plans" or "continue", or similar expressions suggesting future outcomes or events. Such forward-looking statements reflect management's current beliefs and are based on information currently available to management. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those contemplated by such statements. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements including, without limitation, the risks that: (1) the license is not renewed; and, (2) Erin may not achieve the results currently anticipated. Although Erin believes that the expectations reflected in its forward-looking information are reasonable, undue reliance should not be placed on forward-looking information because Erin can give no assurance that such expectations will prove to be correct. In addition to other factors and assumptions which may be identified in this news release, assumptions have been made regarding and are implicit in, among other things, the timely receipt of required regulatory approvals. Details of the risk factors relating to Erin and its business are discussed under the heading “Risks and Uncertainties” in Erin’s most recent regulatory filings which are posted on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list is not exhaustive of all factors and assumptions which have been used. Forward-looking information is based on current expectations, estimates and projections that involve a number of risks and uncertainties which could cause actual results to differ materially from those anticipated by Erin and described in the forward looking information. The forward-looking information contained in this news release is made as of the date hereof and Erin undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, unless required by applicable securities laws. The forward-looking information contained in this news release is expressly qualified by this cautionary statement. Mineral resources are not mineral reserves and do not have demonstrated economic viability. "Inferred Resources" have a great amount of uncertainty as to their existence, and economic and legal feasibility. Investors are cautioned not to assume that all or any part of an inferred mineral resource reported in this news release will ever be upgraded to a higher category or to reserves. U.S. persons are advised that while mineral resources are recognized under Canadian regulations, the U.S. Securities and Exchange Commission does not recognize them. U.S. persons are also cautioned not to assume that all or any part of an inferred mineral resource is economically or legally mineable. #Mining #Resources #ResourceExploration #Boron #BoronAssets #BoronExploration #MininginSerbia #MineDevelopment #Serbia #ResourceStocks #MiningStocks #InvestinginResources #SmallCapStock #FrontierMCG

TORONTO, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“U.S. FDA”) Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19. The Company has selected and finalized with five clinical sites in Florida, Texas and California for enrollment of patients in the Phase 3 clinical study, and is finalizing agreements with an additional ten clinical sites in these states including Arizona and Ohio where patient enrollment should start in October within these other locations. “We have made significant progress in advancing the Phase 3 clinical trial since the FDA approval allowed us to proceed with the study, and we are expanding on and engaging with clinical sites in high prevalence COVID-19 infected states, which will enable us to meet our enrollment goals and expedite the potential FDA approval and commercialization of Bucillamine for the treatment of COVID-19,” said Michael Frank, Revive’s Chief Executive Officer. About the Phase 3 Clinical Trial The Phase 3 confirmatory clinical trial titled, “A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Bucillamine in Patients with Mild-Moderate COVID-19”, will enroll up to 1,000 patients that will be randomized 1:1:1 to receive Bucillamine 100 mg three times a day (“TID”), Bucillamine 200 mg TID or placebo TID for up to 14 days. The primary objective is to compare the frequency of hospitalization or death in patients with mild-moderate COVID-19 receiving Bucillamine therapy with those receiving placebo. The primary endpoint is the proportion of patients meeting a composite endpoint of hospitalization or death from the time of the first dose through Day 28 following randomization. Efficacy will be assessed by comparing clinical outcomes (death or hospitalization), disease severity using the 8-category NIAID COVID ordinal scale, supplemental oxygen use, and progression of COVID‑19 between patients receiving standard-of-care plus Bucillamine (high dose and/or low dose) and patients receiving standard-of-care plus placebo. Safety will be assessed by reported pre-treatment adverse events and treatment-emergent adverse events (including serious adverse events and adverse events of special interest), laboratory values (hematology and serum chemistry), vital signs (heart rate, respiratory rate, and temperature), and peripheral oxygen saturation. An interim analysis will be performed by an Independent Data and Safety Monitoring Board (“DSMB”) after 210 patients have been treated and followed up for 28 days after randomization. The better performing Bucillamine dose at the interim analysis will be selected and patients will then be randomized 2:1 to the selected Bucillamine dose or placebo. Additional interim analyses will be performed after 400, 600, and 800 patients have reached this same post-treatment timepoint. The independent DSMB will actively monitor interim data for the ongoing safety of patients and will recommend continuation, stopping or changes to the conduct of the study based on the interim analysis reports. The Company is not making any express or implied claims that its product has the ability to eliminate or cure COVID-19 (SARS-2 Coronavirus) at this time. Scientific Rationale of Bucillamine for COVID-19 Preclinical and clinical studies have demonstrated that reactive oxygen species contribute to the destruction and programmed cell death of pulmonary epithelial cells.1 N-acetyl-cysteine (NAC) has been shown to significantly attenuate clinical symptoms in respiratory viral infections in animals and humans, primarily via donation of thiols to increase antioxidant activity of cellular glutathione2,3,4,5. Bucillamine (N-(mercapto-2-methylpropionyl)-l-cysteine) has a well-known safety profile and is prescribed in the treatment of rheumatoid arthritis in Japan and South Korea for over 30 years. Bucillamine, a cysteine derivative with two thiol groups, has been shown to be 16 times more potent as a thiol donor in vivo than NAC 6. The drug is non-toxic with high cellular permeability. The basis of the clinical study will analyze if Bucillamine has the potential, via increasing glutathione activity and other anti-inflammatory activity, to lessen the destructive consequences of SARS-CoV2 infection in the lungs and attenuate the clinical course of COVID-19. About Revive Therapeutics Ltd. Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. With its recent acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. Revive’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the company was granted FDA orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation. For more information, visit www.ReviveThera.com. For more information, please contact: Michael Frank Chief Executive Officer Revive Therapeutics Ltd. Tel: 1 888 901 0036 Email: mfrank@revivethera.com Website: www.revivethera.com Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release. Cautionary Statement This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Revive’s current belief or assumptions as to the outcome and timing of such future events. Forward looking information in this press release includes information with respect to the Offering, including the intended use of proceeds. Forward-looking information is based on reasonable assumptions that have been made by Revive at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Revive is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Reference is made to the risk factors disclosed under the heading “Risk Factors” in the Company’s annual MD&A for the fiscal year ended June 30, 2019, which has been filed on SEDAR and is available under the Company’s profile at www.sedar.com. References 1. S Ye et al, Inhibition of Reactive Oxygen Species Production Ameliorates Inflammation Induced by Influenza A Viruses via Upregulation of SOCS1 and SOCS3., American Society for Microbiology. 2015 Mar;89(5):2672-2683). 2. L. Carati et al, Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment., Eur Respir J. 1997 Jul;10(7):1535-41). 3. M Mata et al, N-acetyl-L-cysteine (NAC) inhibit mucin synthesis and pro-inflammatory mediators in alveolar type II epithelial cells infected with influenza virus A and B and with respiratory syncytial virus (RSV)., Biochem Pharmacol. 2011 Sep;82(5):548-55. 4. D Ungheri et al, Protective effect of n-acetylcysteine in a model of influenza infection in mice., Int J Immunopathol Pharmacol. 2000 Sep-Dec;13(3):123-128. 5. RH Zhang et al, N-acetyl-l-cystine (NAC) protects against H9N2 swine influenza virus-induced acute lung injury., Int Immunopharmacol. 2014 Sep;22(1):1-8). 6. LD Horwitz, Bucillamine: a potent thiol donor with multiple clinical applications, Cardiovasc Drug Rev. 2003 Summer;21(2):77-90). SOURCE: #LifeSciences #AlternativeMedicine #DrugRepurposing# DrugDevelopment #Pharmaceuticals #PharmaceuticalSector #MedicalTechnology #Bucillamine #Influenza #Covid19 #InfectiousDiseases #InflammatoryDiseases #Research #MedicalResearch #MedTech #ClinicalTrials #InvestinginMedicine #BiotechStocks #SmallCapStocks #FrontierMCG

TORONTO, ON - August 13, 2020 - Monterey Minerals Inc. (the "Company" or "Monterey") (CSE:MREY and FSE:2DK) is pleased to announce that it has closed the acquisition of Greater Arc Pty Ltd ("Greater Arc"), which owns the Alicia high-grade gold and base metals project in Alicia Municipality, Philippines ("Alicia Project") (see press releases dated February 11, 2020 and May 22, 2020). Greater Arc was purchased from Greater Arc Resources Limited (the former "ParentCo") for 54 million common shares of Monterey, which represents 35.4% of the issued and outstanding shares of Monterey, and becomes the Company's largest shareholder. In connection with this transaction, the Company also paid a finders fee of 5 million common shares. As per the agreement between the parties, Parent Co will not initiate the process of transferring their block of Monterey shares to their shareholders for 180 days from the closing. Monterey will now allocate the majority of the net proceeds to its recently closed oversubscribed private placement to exploration programs in the Philippines (see press releases dated July 9, 2020 and July 28, 2020). Alicia Project Highlights: Greater Arc has identified a system of twelve veins hosting high grade gold and base metal mineralization. The mineralized veins are up to 3.8 m wide and up to 1.7 km in length, with a combined strike length in excess of 11 km. Previous fieldwork at the Alicia Project included detailed geological mapping, geochemical sampling and limited drilling. The twelve veins generally trend northwest-southeast and are grouped into three main vein structures: Sandi Vein in the east Baloy Vein in the central portion of the tenement Pamaraw-Sumihig Vein to the west Several semi-parallel subsidiary veins also occur. Veins host native gold, silver, galena, sphalerite, and pyrite minerals. High grade samples from shallow drilling into the Baloy Vein include: 1.2m of 116 g/t Au, 1,263 g/t Ag, 6.3% Cu, 6.5% Zn, and 47.9% Pb 1.5m of 40.9 g/t Au, 437 g/t Ag, 1.1% Cu, 3.6% Zn, and 62.9% Pb Field Work on the Pamaraw-Sumihig Vein yielded: a drill intersection of 1.5 m of 13.86 g/t Au, 181g/t Ag and 4.8% Cu a grab sample returning 7.51 g/t Au, 55.2 g/t Ag and 1.76% Cu The Alicia Project is situated within a Declared Mineral Reservation determined by the Mines and Geosciences Bureau (MGB) in 1995 and is on a granted Exploration Permit. The Project is accessible by sealed roads, is proximal to power and towns, is 10 km away from a port facility at Malangas, and 60 km from an airport at Pagadian City. 2020 Exploration Plan Highlights: Exploration drilling along strike down to a depth of 300 metres to: Discover the source of the veins at surface and test the geologist's premise that the vein systems are merging at depth Define the down-dip continuity/extension of the vein systems, grade distribution, consistency and vein characteristics Check consistency of zone width and grade at depth below the near surface oxidation zone Begin the groundwork for JORC or NI 43-101 maiden resource Priority Drill targets include: Pamaraw- Sumilhig Area (the "PSA") (see Figure 1) Baloy Vein (see Figure 2) Ground and downhole IP surveys to define the possible extent of mineralization Extended geological mapping, trenching and sampling program https://montereyminerals.com/wp-content/uploads/2020/08/monterey-minerals-corporate-presentation-august-2020.pdf Qualified Person The technical information in this press release has been reviewed and approved by Martin Dormer, a consultant to the Company, who is a Qualified Person as defined by NI 43-101. Martin is a member of the Australian Institute of Mining and Metallurgy (AusIMM), the Australian Institute of Geoscientists (AIG). He is a West Australian geologist with over 22 years' experience and sufficient experience of relevance to the styles of mineralization and types of deposits under consideration to qualify as a Competent Person as defined by the 2012 Edition of the Joint Ore Reserves Committee (JORC) Australian Code for Reporting of Exploration Results, Mineral Resources, and Ore Reserves. About Monterey Minerals Inc. The Company owns 100% of the Alicia Project in the Alicia Municipality of the Philippines. The Alicia Project is a system of multiple, high-grade gold and silver veins with base metals over a strike length of greater than ten kilometres. The Company also owns the Cobalt Mountain Property (the "Property") in the Omineca Mining Division of British Columbia near the town of Smithers. The Company's NI 43-101 technical report, available on SEDAR, notes historic sampling on the Property that returned mineralized showings of gold, silver, copper, zinc and cobalt. The Company also owns 877 sq. km. of prospective Pilbara Basin tenements on the eastern flank of the Pilbara Basin in Western Australia, including a property that abuts Pacton Gold's tenement where gold-bearing conglomerates were identified. For more information, contact investor relations at info@montereyminerals.com On Behalf of the Board of Directors, James Macintosh, President and CEO Neither the Canadian Securities Exchange nor its regulation services provider has reviewed or accepted responsibility for the adequacy or accuracy of this press release This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of the Company. Forward-looking information is based on certain key expectations and assumptions made by the management of the Company. Although the Company believes that the expectations and assumptions on which such forward-looking information is based on are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. The Company disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws. SOURCE: MONTEREY MINERALS INC. #Mining #Gold #GoldMining #GoldExploration #HighGradeGold #SilverExploration #BaseMetals #MininginthePhillipines #GoldStocks #InvestingingGold #MiningStocks #SmallCapStocks #FrontierMCG

Vancouver, B.C. - TheNewswire - October 14, 2020 - Gitennes Exploration Inc. ("Gitennes" or the "Company") (TSXV:GIT) announces that exploration on its three Quebec gold properties will commence in the latter half of October. The properties, JMW, Riviere-a-l'Aigle ("RAL") and New Mosher are all in areas of active exploration (see location map below). JMW Gitennes owns 100% of JMW which is located along the Guercheville Deformation Zone which is host to several high grade prospects as well as the past producing Joe Mann mine. The mine operated 27 of the years from 1956 to 2007 and produced approximately 1.5 million ounces of gold at an average grade of 8.3 g/t gold(1). In addition, the Fenton-Sud Prospect which has a historically reported 426,173 tonnes at a grade of 4.66 g/t gold(1) is located about 12 km northwest of the JMW property on the same trend. Previous work on the JMW property has confirmed the gold bearing structure with gold mineralization within altered and mineralized felsic intrusives within the deformation zone. Gitennes initial exploration programme will consist of mapping, sampling and follow up on several geophysical anomalies. The Company is also conducting a detailed structural analysis of JMW as it appears the favourable gold bearing lithologies are repeated across the property. Readers are cautioned that the Company has no interest in or right to acquire any interest in the Joe Mann mine or Fenton Sud Property, and that mineral deposits and production results from the Joe Mann mine are not indicative of mineral deposits on the Company's properties or any potential exploitation thereof. RAL and New Mosher RAL and New Mosher are under option from Kintavar Exploration and Kintavar will be the operator of the upcoming work programmes on both properties. Kintavar will bring to Gitennes its experience and knowledge of the Quebec geology, infrastructure and logistics on the ground. The team is led by Kintavar's VP Exploration Alain Cayer, P.Geo, recipient of the Bill Denis Prospector of the Year Award for the Eleonore mine discovery with Virginia Gold Mines and also discovered the Anik property along the Guercheville deformation zone, now being advanced in partnership by IAMGOLD and on the same trend as the JMW property. RAL is located adjacent to Osisko Mining Inc.'s Windfall Lake property and consists of 119 claims totalling 6,600 hectares. Work to date on RAL has produced strong geochemical anomalies in tills that appear to be associated with major faults and shear zone axes. Initial work will focus on the three most promising targets that were identified by Kintavar during its most recent work which included till sampling and returned grades up to 3.6 g/t gold (range from 0.1 g/t gold to 3.6 g/t gold). Work will include soil sampling and line cutting with a proposed Induced Polarization geophysical survey to be conducted later in the year. The New Mosher property is approximately five kilometres north east of the Joe Mann mine and consists of 12 claims totaling 670 hectares. Mineralization on New Mosher is within a sheared gabbro and basalt with mesothermal type gold-bearing quartz veins and historically reported sampling revealed grab samples up to 16.7 g/t gold in outcrop and 8.1 g/t gold over 0.25m, 3.03 g/t gold over 1.4m and 2.43 g/t gold over 1.6m in diamond drilling(1). Recent sampling by Kintavar has identified several anomalous areas; however, much of the property remains untested. (1)Readers are cautioned that a "qualified person" (as defined by National Instrument 43-101) has not yet completed sufficient work to be able to verify the historical information, and therefore the information should not be relied upon. The Company also announces that Wayne Holmstead, P.Geo will be joining the Company to act as Manager of Exploration. Wayne is a graduate from the University of Toronto with a B.Sc. in Geology and has over 40 years' experience in mineral exploration and project administration with much of that experience in Quebec. He has managed numerous junior exploration companies and held the position of President, Vice President Exploration and Director. In 2018 Wayne co-founded UrbanGold Minerals and researched and staked many of the properties currently in UrbanGold. Gitennes is also granting 1,875,000 incentive stock options to directors, officers and consultants. Each option is exercisable at $0.165 per share and has a term of five years. This grant of options remains subject to acceptance by the TSX Venture Exchange. About Gitennes Exploration Inc. Gitennes is in the business of exploring for and advancing mineral properties with a focus on high grade gold. The Company currently has three properties in Quebec, JMW, RAL and New Mosher, the Snowbird property in British Columbia and a 1.5% Net Smelter Return royalty on the 18 million ounce Urumalqui Silver Project in Peru. Qualified Person The scientific and technical information contained in this news release has been reviewed and approved by Wayne Holmstead (P.Geo.), who is a "qualified person" within the meaning of National Instrument 43-101. For further information on the Company, readers are referred to the Company's website at www.gitennes.com and its Canadian regulatory filings on SEDAR at www.sedar.com. Gitennes Exploration Inc. "Ken Booth" Ken Booth President For further information, please contact: Ken Booth Phone: 604-682-7970 Email: info@gitennes.com Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. Cautionary Note Regarding Forward-Looking Information This news release includes certain statements that constitute "forward-looking information" within the meaning of applicable Canadian securities laws concerning the business, operations and financial performance and condition of the Company. All statements in this news release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations and orientations regarding the future. Often, but not always, forward-looking statements can be identified by words such as "pro forma", "plans", "expects", "may", "should", "budget", "schedules", estimates", "forecasts", "intends", "anticipates", "believes", "potential" or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Such forward-looking statements include, among others, statements as to the anticipated business plans and timing of future activities of the Company, including the exercise of any property Options and to conduct exploration activities thereon. Actual results could differ from those projected in any forward-looking statements due to numerous factors including risks and uncertainties relating to exploration and development and actual results of exploration activities; the ability of the Company to obtain additional financing; delays in obtaining governmental and regulatory approvals (including of the TSX-V), permits or financing; the need to comply with environmental and governmental regulations; potential defects in title to the Company's properties; fluctuations in the prices of commodities and precious metals; operating hazards and risks; environmental issues and liabilities; and competition and other risks and uncertainties of the mining industry. Although the Company believes that the beliefs, plans, expectations and intentions contained in this news release are reasonable, there can be no assurance that those beliefs, plans, expectations or intentions will prove to be accurate. Readers should consider all of the information set forth herein and should review the Company's periodic reports filed from time-to-time with Canadian securities regulators. These reports and the Company's filings are available at www.sedar.com. Readers are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release and, except as otherwise required by law, the Company undertakes no obligation to update the forward-looking statements contained herein, or to update the reasons why actual results could differ from those projected in these forward-looking statements. SOURCE #Mining #ResourceExploration #GoldMining #GoldExploration #GoldAssets #HighGradeGold #CanadianMining #InvestinginGold #MininginQuebec #SmallCapStocks #FrontierMCG

MONTREAL, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Dominion Water Reserves Corp. (“DWR”), a water reserves holding company, proudly announces the development of its prominent and unique esker water reserve as part of its growth strategy. This unique 5-acre esker water reserve in the Outaouais. With an authorized annual volume of nearly 1 billion liters, this reserve of exceptional quality is now ready for bulk transport and accessible to markets. This source, one of the two authorized eskers in Quebec, contains 9.4% of the volume of Quebec abstraction authorizations, making it the second largest source in authorized volume in Quebec. This exceptional volume of source water under management ensures DWR will become the dominant player in North America in the water market. Considering the unique quality of this esker water DWR is looking to partner with short-term specialty beverage manufacturing to quickly start operations. Along with DWR's portfolio of spring water reserves, which is the only water source in North America containing 13% natural silicon, this source with natural properties is sought after in the specialized water market. A development plan is underway. Our mission is to acquire and manage freshwater a critical mass, in terms of capacity & geography of specialty water assets and secure a leadership role in North America’s water market while prioritizing sustainability and environmental consciousness. DWR further announces, as part of its expansion and development plans to welcome back Marie-Claude Bourgie as Interim President, with her expertise in providing executive strategic direction across natural resource markets and climate change initiatives. With previous roles such as Chief Development Officer at One Drop Foundation, her strong belief in DWR’s growth potential and playing a major role in the structure of the firm, Marie-Claude Bourgie is a welcome addition to the firm’s management as Norman Forrest and Edward Ierfino resign from their posts. About Dominion Water Reserves Corp. DWR’s operations are based in Quebec, with its primary business being a consolidator of the water industry by acquiring fresh spring water permits and developing operations across Quebec with plans to expand across North America. DWR currently controls more than 30% of Quebec’s volume of fresh groundwater reserves currently under permit and is strategically positioned to increase its holding. DWR’s mission is to acquire, manage and develop spring water assets building a critical mass in terms of capacity and strategically securing a leadership role in North America’s fresh spring water. The corporation prioritizes sustainability and environmental consciousness. A strong governance structure is in place to ensure that the corporation carries out its business responsibly, applying the highest social and environmental standards. For further information please contact Jean Gosselin Phone: 514-707-0223 Email: jgosselin@dwrcorp.net Neither the CSE nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release. SOURCE #SpringWaterPermits #SpringWaterAssets #FreshWaterSupply #NorthAmericaFreshWater #WaterAssets #WaterReserves #SmallCapStocks #CSE #InvestinginWaterAssets #FrontierMCG

VANCOUVER, British Columbia, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that the first patient has been dosed in its Phase 2 idiopathic pulmonary fibrosis (IPF) and chronic cough clinical study of its re-purposed drug NP-120 (Ifenprodil). The patient was enrolled and dosed at the Waikato Hospital located in Hampton, New Zealand. Phase 2 Study Summary: The purpose of this proof-of-concept Phase 2 human trial is to determine the efficacy of Ifenprodil in the preservation of lung function in IPF patients (including biomarkers of fibrosis) and its associated cough. There are 5 sites in total participating in the study with 3 located in Australia and 2 in New Zealand. Ifenprodil has been shown to mediate anti-inflammatory responses and reduce pulmonary fibrosis in a murine model of Idiopathic Pulmonary Fibrosis (IPF). In addition, Ifenprodil significantly reduced both cough frequency and onset in a guinea pig acute cough model. The Company would like to thank its Medical and Scientific Advisory Board Members, Dr. Martin Kolb and Dr. Jacky Smith, for their collective contributions to the Phase 2 study design. Dr. Kolb is the Moran Campbell Chair and Professor in Respiratory Medicine and Director of the Division of Respirology, McMaster University, and is a leading global scientific expert and clinician in the area of IPF. Dr. Jacky Smith is a Professor of Respiratory Medicine, University of Manchester, and is a leading global scientific expert and clinician in the area of understanding the mechanisms underlying cough in respiratory diseases and the testing of novel anti-tussive therapies. “Ifenprodil showed very promising results in our IPF and cough pre-clinical studies and so I am very pleased to announce our first patient in and the formal start of our clinical program,” said Christopher J. Moreau, CEO of Algernon Pharmaceuticals. “As the study progresses, the Company will make an assessment of the enrollment rate and will provide an update to the market on a projected completion date as well as when the data will be expected.” About NP-120 (Ifenprodil) NP-120 (Ifenprodil) is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (Glu2NB). Ifenprodil prevents glutamate signalling. The NMDA receptor is found on many tissues including lung cells, T-cells, and neutrophils. Additional: The Company announces that since the financing that closed on May 13, 2020, the Company has issued 5,300,000 common shares upon the exercise of common share purchase warrants, for net proceeds to the Company of $636,000. About Algernon Pharmaceuticals Inc. Algernon is a drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing. Algernon has filed new intellectual property rights globally for NP-120 (Ifenprodil) for the treatment of respiratory diseases and is working to develop a proprietary injectable and slow release formulation. CONTACT INFORMATION Christopher J. Moreau CEO Algernon Pharmaceuticals Inc. 604.398.4175 ext 701 info@algernonpharmaceuticals.com investors@algernonpharmaceuticals.com www.algernonpharmaceuticals.com The CSE does not accept responsibility for the adequacy or accuracy of this release. Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law. SOURCE #Technology #MedicalTechnology #Medtech #DrugDiscovery #MedicalResearch #MedicalDevices #PharmaceuticalDevelopment #BreathAnalysis #FAIMS #DrugRepurosing #RespiratoryMedicine #RespiratoryIllness #ClinicalTrials #HumanTrials #MedicalTechnology #MedicalAdvancements #DrugDevelopment #Research #MedicalBreakthrough #Coronavirus #COVID19 #Biotech #BiotechStocks #InvestinginHealthcare #InvestinginMedicine #SmallCapStocks #FrontierMCG

Algernon Announces Data and Safety Monitoring Board Recommends the Continuation of its Multinational 2b/3 Human Study of Ifenprodil for Treatment of COVID-19 VANCOUVER, British Columbia, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that the external Data and Safety Monitoring Board (DSMB) has unanimously approved the continuation of its multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19. The DSMB is a committee of clinical research experts, such as physicians and statisticians, and patient advocates who monitor the progress of a clinical trial and review safety and effectiveness data while the trial is ongoing. This recommendation from the DSMB is encouraging because it confirms that there are no significant safety concerns in the study groups being treated with Ifenprodil. “We are very pleased with the unanimous decision of the DSMB to carry on with the study,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals. “It confirms what we had previously identified regarding Ifenprodil’s long standing safety history.” Phase 2b/3 Study Protocol Summary The Company’s multinational Phase 2b/3 human trial for COVID-19 is entitled, "A Randomized Open Label Phase 2b/3 Study of the Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patients with Confirmed COVID-19 Disease." The trial is currently underway as a Phase 2b study of an aggregate of 150 patients. With positive preliminary data, the clinical trial will move directly into a Phase 3 trial. The data from the Phase 2b study will determine the number of patients needed to reach statistical significance in the Phase 3 trial. Patients are being randomized in a one-to-one manner and are either being treated using an existing standard of care, or standard of care plus Ifenprodil 60 mg (taken as one 20 mg tablet three-times daily) for one arm or standard of care plus Ifenprodil 120 mg (taken as two 20 mg tablets three-times daily) for two weeks. Over the testing period, doctors will observe whether there is an improvement in a number of secondary endpoints, including mortality, blood oxygen levels, time spent in intensive care and time to mechanical ventilation. Phase 2b Study Completion and Data Readout The Company will provide an update to the market on a projected completion date of the study as well as when the read out of the data can be expected when enrollment in the study reaches the 50% target level. About NP-120 (Ifenprodil) NP-120 (Ifenprodil) is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (Glu2NB). Ifenprodil prevents glutamate signalling. The NMDA receptor is found on many tissues including lung cells, T-cells, and neutrophils. The Company believes Ifenprodil can reduce the infiltration of neutrophils and T-cells into the lungs where they can release glutamate and cytokines respectively. The latter can result in the highly problematic cytokine storm that contributes to the loss of lung function and ultimately death as has been reported in COVID-19 infected patients. About Algernon Pharmaceuticals Inc. Algernon is a drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing. Algernon has filed new intellectual property rights globally for NP-120 (Ifenprodil) for the treatment of respiratory diseases and is working to develop a proprietary injectable and slow release formulation. CONTACT INFORMATION Christopher J. Moreau CEO Algernon Pharmaceuticals Inc. 604.398.4175 ext 701  info@algernonpharmaceuticals.com investors@algernonpharmaceuticals.com www.algernonpharmaceuticals.com The CSE does not accept responsibility for the adequacy or accuracy of this release. Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law. #Technology #MedicalTechnology #Medtech #DrugDiscovery #MedicalResearch #MedicalDevices #PharmaceuticalDevelopment #BreathAnalysis #FAIMS #DrugRepurosing #RespiratoryMedicine #RespiratoryIllness #ClinicalTrials #HumanTrials #MedicalTechnology #MedicalAdvancements #DrugDevelopment #Research #MedicalBreakthrough #Coronavirus #COVID19 #Biotech #BiotechStocks #InvestinginHealthcare #InvestinginMedicine #SmallCapStocks #FrontierMCG

Launch of Maestro further expands the Marble platform with this educational component, as November marks the 10th anniversary of Financial Literacy Month in Canada Vancouver, B.C. - TheNewswire - October 28, 2020 - Marble Financial Inc. (CSE:MRBL) (CNSX:MRBL.CN) (OTC:MRBLF) ("Marble" or the "Company") a financial technology company that empowers Canadians' toward a positive financial future, is pleased to announce the launch of Maestro, Marble's latest financial literacy educational platform, available to all MyMarble customers. Maestro combines expert-curated educational content and skill testing quizzes to give Canadians the power to have both a foundation in crucial financial knowledge and the empowerment to effectively utilize Marble's personal finance and credit rebuilding platform, MyMarble and its current products, Score-Up, and Fast-Track. Maestro users will benefit from over 30 different courses across three core financial foundations, credit, budget, and debt management. Key findings from Statistics Canada's 2019 Canadian Financial Capability Survey showed that 51% of 18 to 35 year-old Canadians surveyed seek financial literacy from online sources, displaying a preference for easy-to-use and digestible online content. In addition to this, 44% of Canadians surveyed said they engaged in financial education to strengthen their financial knowledge, proving a high demand and additional user acquisition stream with a product such as Maestro. November marks the 10th anniversary of Financial Literacy Month in Canada, and today, millions of Canadians are still seeking some form of online financial education. The launch of Maestro adds an additional dimension to Marble's product line, allowing Marble to become its users' primary personal finance solution through a more holistic, end-to-end financial experience. Maestro is now available on the MyMarble Platform and offers the following: Available to all Marble customers at no cost, monthly fees or subscription Over thirty expert-curated online courses in the credit, budget and debt management sectors Desktop and mobile friendly Video enabled and audio course content for all audiences "Canadian's are used to the traditional ways when it comes to improving their financial literacy - friends or family, financial advisors, or banks," said Karim Nanji, CEO of Marble. "The description of a 'Maestro' is someone who conducts and is a master of their respective trade. The ability to master finances is something we believe all Canadians can achieve through financial literacy offered in an effective and easy online-learning environment. With Marble's Maestro, we are very excited to fill the demand to further empower and educate Canadians. With the power of our online technology and our industry-leading MyMarble, Score-Up, and Fast-Track solutions, our customers have all the tools needed to take control of their personal finances." ON BEHALF OF THE BOARD OF DIRECTORS, Karim Nanji, CEO About Marble Financial Inc. (CSE: MRBL; OTC: MRBLF) Marble leverages its proven data driven strategies utilizing the power of machine learning, data science, and artificial intelligence, through its industry-leading proprietary technology solutions Fast-Track, Score-Up, and Credit-Meds to engage in and navigate a clear path for Canadians towards financial wellbeing and a meaningful credit score. Since 2016, Marble is proud to have empowered thousands of marginalized Canadians to a positive financial future, and we continue to establish ourselves as leaders in financial wellness through the licensing of our proprietary products on the Marble Platform. For further information, please visit the company's website at http://mymarble.ca Mike Marrandino, Executive Chairman T:(855) 661-2390 ext. 104 Email: ir@marblefinancial.ca NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. Caution Regarding Forward-Looking Information This release contains "forward-looking information" as such term is used in applicable Canadian securities laws, including statements regarding the Private Placement and the use of proceeds therefrom. The use of any of the words "target", "plans", "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Such forward-looking information is based on management's expectations and assumptions, including statements relating to the future plans and objectives of the Company, the Company's expectations surrounding the market potential of Maestro, Score-Up, Fast Track and the benefits including potential credit score improvement, building and management results. In making the forward-looking statements included in this news release, the Company has applied several material assumptions, including but not limited to, that the Company's financial condition and development plans do not change as a result of unforeseen events, and that the Company will and has received all required regulatory approvals in the jurisdictions across Canada that it will be offering this product. Forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause plans, estimates and actual results to vary materially from those projected in such forward-looking information. Factors that could cause the forward-looking information in this news release to change or to be inaccurate include, but are not limited to: general economic, market or business conditions; changes in the Company's financial condition and development plans; and other risks and uncertainties as set forth in the Company's most recent continuous disclosure filings filed under the Company's profile at www.sedar.com. Although the Company has attempted to consider important factors that could cause actual costs or results to differ materially, there may be other factors that cause actual results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The forward-looking information included in this release is expressly qualified in its entirety by this cautionary statement. Accordingly, readers should not place undue reliance on forward-looking information. The Company undertakes no obligation to update these forward-looking statements, other than as required by applicable law. SOURCE #Fintech #Technology #AI #Data #Finance #PersonalFinance #FinancialFuture #FinancialLiteracy #FinancialLiteracyMonth #Credit #CreditRebuilding #CreditSolutions #CreditRepair #TechStocks #FinTechStocks #FrontierMCG

Lithium Chile Announces 26 gms/tonne Gold and 256 gms/tonne Silver from Initial Programme on Its 100% Owned Carmona Property Calgary, Alberta--(Newsfile Corp. - September 3, 2020) - Lithium Chile Inc. (TSXV: LITH) (OTC Pink: LTMCF) ("Lithium Chile" or the "Company") is pleased to announce it has received assay results from the first batch of samples taken from its 100% owned Carmona gold silver property. These initial sample results support the potential for Carmona to host a number of gold/silver bearing zones. There were a number of high-grade intercepts identified from this initial sampling program. The highlights are as follows: Gold and silver values from rock samples range from 0.5 to 26.2 g/t gold and 2.1 to 256 g/t silver; Highest grade sample of 26.2 g/t gold is from newly discovered zone within the northern half of a 13 km2 central area; Phase 1 samples are from the central core alteration zone which lies along a structural axis through the central portion of the property; Anomalous samples cluster into three main areas from six to 13 km2 and totaling 26 km2; The southernmost area includes several old mine workings and rock samples from some of these workings ranged from 12.4 to 18.3 g/t gold and 95.4 to 231 g/t silver over widths of 1.5 to 2.0 meters The Company expects to receive assays from an additional batch of rock samples by mid month. The exploration team returned to the property on August 28 to start the phase 2 detailed follow up sampling and trenching program on an expedited basis. Map 1 To view an enhanced version of Map 1, please visit: https://orders.newsfilecorp.com/files/5962/63144_5df5b4a574fe4965_001full.jpg Steve Cochrane, President and CEO of Lithium Chile, comments, "We are extremely pleased from the initial sample results from our Carmona gold/silver prospect. These early samples confirm the potential for Carmona to host a number of gold/silver deposits. We now have an expanded exploration program on the property underway and look forward to additional results soon. With the high level of interest in gold these days and indeed Lithium Chile's gold properties, it is our intention to advance exploration development on these prospects as quickly as possible." Qualified Person Mr. Terence Walker, M.Sc., P.Geo, qualified person within the meaning of National Instrument 43-101, has reviewed the contents of this news release. During the course of the exploration program all samples were collected by experienced Lithium Chile staff. Each sediment was sieved in the field to obtain about I kg of -18 mesh fines, bagged and sealed on site. Each rock sample consisted of 1 -1.5 kg of representative chips taken continuously from outcrop or across mineralized structures, was bagged and sealed on site. All samples were delivered by Lithium Chiles staff to the ALS prep-lab in La Serena for processing. ALS subsequently shipped a 30g sub-sample pulp to their laboratory in Lima, Peru where they were analyzed for gold by fire assay pre-concentration, AA finish and 35 other elements, including copper and silver, by the ICP technique following Agua Regia digestion. About Lithium Chile Lithium Chile is advancing a lithium property portfolio consisting of 110,280 hectares covering sections of 11 salars and two laguna complexes in Chile. Lithium Chile now also owns 5 properties that are prospective for gold, silver and copper. The Carmona and La Fortuna properties lie in the heart of the Chilean Maricunga gold belt. Lithium Chile's common shares are listed on the TSX-V under the symbol "LITH" and on the OTC-BB under the symbol "LTMCF". To find out more about Lithium Chile Inc., please contact Steven Cochrane, President and CEO via email: steve@lithiumchile.ca or alternately, Jeremy Ross, Business Development, at (604) 537-7556 or via email: jeremy@lithiumchile.ca. Chilean contact is Terry Walker, VP Exploration at (011) 562 2455-6473 or via email: twalker@goldenrock.cl. NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. NOT FOR RELEASE IN THE UNITED STATES OF AMERICA Forward Looking Statements This news release may contain certain forward-looking information and forward-looking statements within the meaning of applicable securities legislation (collectively "forward-looking statements"). Generally, forward-looking information can be identified by the use of forward-looking terminology such as "expects", "believes", "aims to", "plans to" or "intends to" or variations of such words and phrases or statements that certain actions, events or results "will" occur. In particular, this news release contains forward-looking statements relating to, among other things, the closing of the second tranche of the private placement, statements pertaining to the use of proceeds, and the Company's ability to obtain necessary approvals from the TSX Venture Exchange. You are cautioned that the following list of material factors and assumptions is not exhaustive. Specific material factors and assumptions include, but are not limited to: the general stability of the economic and political environment in which the Company operates; the timely receipt of required regulatory approvals; the ability of the Company to obtain future financing on acceptable terms; currency, exchange and interest rates; operating costs; the success the Company will have in exploring its prospects and the results from such prospects. Accordingly, readers should not place undue reliance on forward-looking statements. The Company does not undertake to update any forward-looking statements herein, except as required by applicable securities laws. All forward-looking statements contained in this news release are expressly qualified by this cautionary statement. SOURCE #Mining #Gold #GoldExploration #Silver #SilverExploration #HighGradeSilver #ResourceExploration #GoldMining #SIlverMining #HighGradeGold #GoldProject #CanadianResources #CanadianExploration #CanadianGoldMining #MiningStocks #GoldStocks #InvestinginGold #SmallCapStocks #FrontierMCG

TORONTO, ON / ACCESSWIRE / July 14, 2020 / KABN Systems NA Holdings Corp. (CSE:KABN) (the "Company" or "KABN" or "KABN North America"), a Canadian Fintech company that specializes in continuous online identity verification, management and monetization in Canada and the US, is pleased to announce that later this summer its Liquid Avatar platform (www.liquidavatar.com), will begin to offer users with a new type of Avatar experience through the Liquid Avatar Marketplace ("Marketplace"). Liquid Avatar users will be able to acquire custom-designed and limited availability icons from leading professional pop culture, comic book, fantasy, manga, and contemporary Artists complete with an innovative digital authentication solution that has been traditionally managed as an on-site, personnel and location-based process. All Liquid Avatars acquired from the Marketplace will be supported with a unique Digital Certificate of Authenticity, allowing each custom icon to have its own Blockchain identifier that can be transferred from one user to another. This methodology created by the KABN Network and supported by Blockchain technologies, will allow users to buy, sell and trade custom avatars and record the transfer and ownership of these collectible icons. The Marketplace will charge a fee for the issuance, recording, and management of the Digital Certificate of Authenticity and the transfer of ownership of digitized assets. "The creation and distribution of Digital Certificates of Authenticity featuring unique Blockchain technologies for custom Liquid Avatars is a key business strategy for KABN North America," said RJ Reiser, Chief Business Development Officer. "Like hockey, baseball and basketball cards, other sports, comic books, movie props, and signed memorabilia, we believe that digitized assets will represent a viable way for online audiences to be part of the growing collector community." In addition, as part of the Liquid Avatar Creator Program, icons can be designed to represent different "skins" for a user's verified persona, like a school, gaming, family, friends, and business/work profile. Recently, Liquid Avatar, in partnership with the NCFA (www.ncfacanada.org), released a custom event icon for FFCON20 - Rise (https://www.accesswire.com/viewarticle.aspx?id=596745). This process allows users, businesses, events, associations, and other groups to create unique icons for their verified online groups and share content and offers with known users. The Liquid Avatar Marketplace has over 20 professional creators on board already and 10 engaged in the creation process. In addition to a growing list of free Liquid Avatars, the Marketplace will have the ability to showcase a catalog of approved custom avatars for sale. Additional items like t-Shirts, hoodies, and other items featuring certain Liquid Avatars will be available for sale. KABN North America will be presenting Liquid Avatar with Apex Comic Group at this year's virtual Comic-con International @home program on Saturday, July 25, 2020 at 5 pm Pacific / 8 pm Eastern - https://comiccon2020.sched.com/event/d4zK/apex-comics-publishing-group-2020-2021-exclusive-previews The Company welcomes the public to request an invitation to be an early adopter of Liquid Avatar and earn rewards at: https://liquidavatar.com/liquid-avatar-early-adopter/ "Liquid Avatar custom icons represent a potentially significant opportunity to create revenue for KABN North America," said Ben Kessler, CEO. "Anyone who knows a Fortnite player or other gamer knows that players are always looking to acquire the latest cosmetic enhancement and along with sports, comic book, movie and fantasy collectors, we believe we are targeting the right audience for our custom and collectible Liquid Avatars." About KABN North America - www.kabnnaholdco.com KABN Systems NA Holdings Corp. through its wholly-owned subsidiary KABN Systems North America Inc. focuses on the verification, management and monetization of digital identity, empowering users to control and benefit from its use of their online identity. KABN propriety technology suite includes 4 key products: KABN ID is an Always On, biometric and blockchain based digital identity validation and verification platform allowing users to continuously and confidently prove themselves throughout the online community. Liquid Avatar allows users to create high-quality digital icons representing their online personas. These icons, in conjunction with KABN ID, allows users to use Liquid Avatars to share public and permission-based private data when they want and with whom they want. www.liquidavatar.com KABN Card is a Visa approved prepaid card program allowing users to manage both digital and fiat currencies, and earn cashback and other loyalty incentives. www.kabncard.com KABN KASH is a cashback, loyalty and engagement program that powers the KABN revenue ecosystem. KABN provides its products and services at no cost to consumers and generates revenues through permission-based partner programs. www.kabnkash.com KABN Systems NA Holdings Corp. is publicly traded on the Canadian Securities Exchange under the symbol: KABN For more information, please visit www.kabnnaholdco.com or www.kabnsystemsna.com For further information, please contact: Ben Kessler Chief Executive Officer 647-725-7742 Ext. 700 ir@kabnsystemsna.com The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities under the KABN Financing in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. Forward-Looking Information and Statements This press release contains certain "forward-looking information" within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company's beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company's control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or may contain statements that certain actions, events or results "may", "could", "would", "might" or "will be taken", "will continue", "will occur" or "will be achieved". The forward-looking information and forward-looking statements contained herein may include, but is not limited to, information concerning the ability of the Company to generate revenues, roll out new programs and to successfully achieve business objectives, and expectations for other economic, business, and/or competitive factors. By identifying such information and statements in this manner, the Company is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, the Company has made certain assumptions. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information and statements are the following: changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws; compliance with extensive government regulation. Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to the Company or persons acting on its behalf is expressly qualified in its entirety by this notice. SOURCE: #Technology #DisruptiveTechnology #KYC #AML #OnlineIdentity #PersonalData #OwnYourData #Data #OnlineSecurity #DataSecurity #DataProtection #GDPR #FinancialServices #DigitalWallet #BankingAlternatives #DigitalBanking #Blockchain #Fintech #DigitalCurrency #Cryptocurrencies #Crypto #LiquidAvatar #InvestinginTech #TechStocks #FrontierMCG

Algernon Announces Enrollment of First U.S. Patient in Multinational Phase 2b/3 Human Study of Ifenprodil for Treatment of COVID-19 VANCOUVER, British Columbia, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it has enrolled its first patient from the U.S. for its multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19. The Company is also pleased to announce that it has now enrolled 26 patients since the study began on August 5, 2020. The Phase 2b/3 study enrollment target is 150 patients, aggregated from all participating sites. “We are very pleased to announce our first U.S. patient,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals. “We have also had steady enrollment from one of our International sites and as a result, we expect to reach 25% of our total target shortly.” Phase 2b/3 Study Protocol Summary The Company’s multinational Phase 2b/3 human trial for COVID-19 is entitled, "A Randomized Open Label Phase 2b/3 Study of the Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patients with Confirmed COVID-19 Disease." The trial will begin as a Phase 2b study of an aggregate of 150 patients. With positive preliminary data, the clinical trial will move directly into a Phase 3 trial. The data from the Phase 2b study will determine the number of patients needed to reach statistical significance in the Phase 3 trial. Patients will be randomized in a one-to-one manner and will either be treated using an existing standard of care, or standard of care plus Ifenprodil 60 mg (taken as one 20 mg tablet three-times daily) for one arm or standard of care plus Ifenprodil 120 mg (taken as two 20 mg tablets three-times daily) for two weeks. Over the testing period, doctors will observe whether there is an improvement in a number of secondary endpoints, including mortality, blood oxygen levels, time spent in intensive care and time to mechanical ventilation. Phase 2b Study Completion and Data Readout The Company will provide an update to the market shortly on a projected completion date as well as when the read out of the data can be expected. About NP-120 (Ifenprodil) NP-120 (Ifenprodil) is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (Glu2NB). Ifenprodil prevents glutamate signalling. The NMDA receptor is found on many tissues including lung cells, T-cells, and neutrophils. The Company believes Ifenprodil can reduce the infiltration of neutrophils and T-cells into the lungs where they can release glutamate and cytokines respectively. The latter can result in the highly problematic cytokine storm that contributes to the loss of lung function and ultimately death as has been reported in COVID-19 infected patients. About Algernon Pharmaceuticals Inc. Algernon is a drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing. Algernon has filed new intellectual property rights globally for NP-120 (Ifenprodil) for the treatment of respiratory diseases and is working to develop a proprietary injectable and slow release formulation. CONTACT INFORMATION Christopher J. Moreau CEO Algernon Pharmaceuticals Inc. 604.398.4175 ext 701 info@algernonpharmaceuticals.com investors@algernonpharmaceuticals.com www.algernonpharmaceuticals.com The CSE does not accept responsibility for the adequacy or accuracy of this release. Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law. SOURCE #Technology #MedicalTechnology #Medtech #DrugDiscovery #MedicalResearch #MedicalDevices #PharmaceuticalDevelopment #BreathAnalysis #FAIMS #DrugRepurosing #RespiratoryMedicine #RespiratoryIllness #ClinicalTrials #HumanTrials #MedicalTechnology #MedicalAdvancements #DrugDevelopment #Research #MedicalBreakthrough #Coronavirus #COVID19 #Biotech #BiotechStocks #InvestinginHealthcare #InvestinginMedicine #SmallCapStocks #FrontierMCG